

# Takaomi Sanda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7957286/publications.pdf>

Version: 2024-02-01

86  
papers

6,760  
citations

87843

38  
h-index

64755

79  
g-index

87  
all docs

87  
docs citations

87  
times ranked

12288  
citing authors

#	ARTICLE	IF	CITATIONS
1	Activating mutations in ALK provide a therapeutic target in neuroblastoma. <i>Nature</i> , 2008, 455, 975-978.	13.7	775
2	Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. <i>Nature</i> , 2014, 511, 616-620.	13.7	698
3	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. <i>Science</i> , 2014, 346, 1373-1377.	6.0	665
4	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 647-650.	0.6	414
5	The Requirement for Cyclin D Function in Tumor Maintenance. <i>Cancer Cell</i> , 2012, 22, 438-451.	7.7	284
6	The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. <i>Cancer Cell</i> , 2012, 22, 117-130.	7.7	270
7	Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 209-221.	7.7	262
8	Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. <i>Leukemia</i> , 2013, 27, 66-74.	3.3	166
9	The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 4169-4173.	0.6	162
10	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. <i>Nature Medicine</i> , 2012, 18, 1118-1122.	15.2	162
11	<sc>KPT</sc>â€³30 inhibitor of <sc>CRM</sc>1 (<sc>XPO</sc>1)â€mediated nuclear export has selective antiâ€leukaemic activity in preclinical models of <sc>T</sc>â€cell acute lymphoblastic leukaemia and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 161, 117-127.	1.2	149
12	T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. <i>Cancer Cell</i> , 2010, 18, 353-366.	7.7	141
13	TYK2â€STAT1â€BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2013, 3, 564-577.	7.7	122
14	Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 2845-2851.	0.6	112
15	The TAL1 complex targets the <i>FBXW7</i> tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2013, 210, 1545-1557.	4.2	107
16	Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. <i>Journal of Experimental Medicine</i> , 2011, 208, 663-675.	4.2	106
17	Phosphatase-Dependent and -Independent Functions of Shp2 in Neural Crest Cells Underlie LEOPARD Syndrome Pathogenesis. <i>Developmental Cell</i> , 2010, 18, 750-762.	3.1	96
18	Absence of Biallelic <i>TCR</i> <sup>3</sup> Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3816-3823.	0.8	93

#	ARTICLE	IF	CITATIONS
19	Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. <i>Journal of Biological Chemistry</i> , 2012, 287, 9742-9752.	1.6	89
20	The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , 2016, 7, 10258.	5.8	87
21	PIDD Death-Domain Phosphorylation by ATM Controls Prodeath versus Prosurvival PIDDosome Signaling. <i>Molecular Cell</i> , 2012, 47, 681-693.	4.5	78
22	RNA helicase hA interacts with nuclear factor $\kappa$ B p65 and functions as a transcriptional coactivator. <i>FEBS Journal</i> , 2004, 271, 3741-3751.	0.2	77
23	ATM-deficient thymic lymphoma is associated with aberrant <i>tcrd</i> rearrangement and gene amplification. <i>Journal of Experimental Medicine</i> , 2010, 207, 1369-1380.	4.2	74
24	Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in <i>ALK</i> -mutated neuroblastoma. <i>Oncotarget</i> , 2014, 5, 8737-8749.	0.8	72
25	Growth Inhibition of Multiple Myeloma Cells by a Novel $\kappa$ B Kinase Inhibitor. <i>Clinical Cancer Research</i> , 2005, 11, 1974-1982.	3.2	68
26	Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. <i>Blood</i> , 2017, 130, 2326-2338.	0.6	66
27	Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. <i>Leukemia</i> , 2012, 26, 2233-2244.	3.3	64
28	Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 1735-1745.	0.6	61
29	Ribonucleoprotein HNRNPA2B1 Interacts With and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells. <i>Gastroenterology</i> , 2014, 147, 882-892.e8.	0.6	56
30	ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. <i>Nature Communications</i> , 2019, 10, 5622.	5.8	56
31	APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. <i>Leukemia</i> , 2017, 31, 2057-2064.	3.3	54
32	The enhancer RNA ARIEL activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2019, 134, 239-251.	0.6	54
33	Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2249-2259.	1.9	53
34	ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis. <i>Genes and Development</i> , 2017, 31, 2343-2360.	2.7	51
35	Induction of cell death in adult T-cell leukemia cells by a novel $\kappa$ B kinase inhibitor. <i>Leukemia</i> , 2006, 20, 590-598.	3.3	47
36	The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis. <i>Leukemia</i> , 2016, 30, 1365-1374.	3.3	44

#	ARTICLE	IF	CITATIONS
37	TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia. <i>Experimental Hematology</i> , 2017, 53, 7-15.	0.2	41
38	Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. <i>Leukemia</i> , 2007, 21, 2344-2353.	3.3	40
39	Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer. <i>ACS Chemical Biology</i> , 2013, 8, 1423-1428.	1.6	40
40	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2019, 33, 696-709.	3.3	40
41	BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. <i>Leukemia</i> , 2014, 28, 1145-1148.	3.3	38
42	Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 2138-2151.	3.3	38
43	HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2016, 30, 219-228.	3.3	36
44	Overexpression of carboxylesterase 2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma. <i>Cancer Science</i> , 2008, 99, 2309-2314.	1.7	33
45	Emi1 Maintains Genomic Integrity during Zebrafish Embryogenesis and Cooperates with p53 in Tumor Suppression. <i>Molecular and Cellular Biology</i> , 2009, 29, 5911-5922.	1.1	33
46	Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2017, 7, 218.	1.3	32
47	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1350-1357.	3.0	32
48	Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017, 177, 271-282.	1.2	28
49	Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 1798-1807.	3.3	28
50	Feed-forward regulatory loop driven by IRF4 and NF- $\kappa$ B in adult T-cell leukemia/lymphoma. <i>Blood</i> , 2020, 135, 934-947.	0.6	28
51	Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis. <i>Leukemia</i> , 2005, 19, 901-909.	3.3	26
52	Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon- $\gamma$ (MIG) gene expression in B-cell malignancy. <i>Leukemia</i> , 2005, 19, 1471-1478.	3.3	26
53	Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2019, 109, 5-17.	0.7	25
54	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 1929-1945.	4.2	22

#	ARTICLE	IF	CITATIONS
55	Sphingosine 1-Phosphate Receptor 2 Induces Otoprotective Responses to Cisplatin Treatment. <i>Cancers</i> , 2020, 12, 211.	1.7	22
56	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
57	Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma. <i>Cancer Research</i> , 2022, 82, 406-418.	0.4	18
58	TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2016, 30, 959-962.	3.3	17
59	Severe Hypercholesterolemia Associated with Decreased Hepatic Triglyceride Lipase Activity and Pseudohyponatremia in Patients after Allogeneic Stem Cell Transplantation. <i>International Journal of Hematology</i> , 2005, 82, 362-366.	0.7	15
60	Roles of the RUNX1 Enhancer in Normal Hematopoiesis and Leukemogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 962, 139-147.	0.8	15
61	Knock down of hSNF5/Ini1 causes cell cycle arrest and apoptosis in a p53-dependent manner. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 580-585.	1.0	14
62	Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma. <i>Haematologica</i> , 2018, 103, 2059-2068.	1.7	14
63	Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 32.	2.8	14
64	Mutationally Activated TYK2 From T-ALL Specimens Exhibits Transformative Capacity in Cell Lines and Primary Cell Models and T-Lineage Expansion in Mice. <i>Blood</i> , 2011, 118, 74-74.	0.6	14
65	Successful Treatment of Nasal T-Cell Lymphoma With a Combination of Local Irradiation and High-Dose Chemotherapy. <i>International Journal of Hematology</i> , 2002, 75, 195-200.	0.7	11
66	RUNX1 point mutations potentially identify a subset of early immature T-cell acute lymphoblastic leukaemia that may originate from differentiated T-cells. <i>Gene</i> , 2014, 545, 111-116.	1.0	9
67	Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia. <i>Molecules</i> , 2018, 23, 1057.	1.7	9
68	Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines. <i>Gene</i> , 2021, 774, 145421.	1.0	9
69	Induction of class II major histocompatibility complex expression in human multiple myeloma cells by retinoid. <i>Haematologica</i> , 2007, 92, 115-120.	1.7	8
70	KPT-SINE, a Potent, Small Molecule Inhibitor of CRM1-Dependent Nuclear-Cytoplasmic Shuttling, with Potent Activity Against T-ALL and AML. <i>Blood</i> , 2011, 118, 2622-2622.	0.6	8
71	IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma. <i>Nature Communications</i> , 2022, 13, 2420.	5.8	5
72	RUNX1 in T-ALL: tumor suppressive or oncogenic?. <i>Blood</i> , 2017, 130, 1686-1688.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Transcription Factors as Therapeutic Targets in Lymphoid Malignancies. International Reviews of Immunology, 2007, 26, 305-332.	1.5	3
74	Oncorequisite role of an aldehyde dehydrogenase in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica, 2021, 106, 1545-1558.	1.7	2
75	Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition. Blood, 2011, 118, 1405-1405.	0.6	2
76	Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling. Blood Advances, 2022, 6, 5330-5344.	2.5	2
77	Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia.. Blood, 2010, 116, 1042-1042.	0.6	1
78	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1470-1470.	0.6	1
79	Abstract 1180: The TCA cycle transferase DLST is critical for MYC-mediated leukemogenesis. , 2016, , .		1
80	Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma. Blood, 2020, 136, 17-17.	0.6	1
81	Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 3155-3155.	0.6	0
82	The BCL11B Tumor Suppressor Is Mutated In Human T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 4177-4177.	0.6	0
83	Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in T-Cell Acute Lymphoblastic Leukemia,. Blood, 2011, 118, 3453-3453.	0.6	0
84	The TAL1 Complex Represses the FBXW7 Tumor Suppressor Through Mir-223 in Human T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1296-1296.	0.6	0
85	HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase. Blood, 2013, 122, 2528-2528.	0.6	0
86	A Genetic Screen In Zebrafish Identified Dlst As a Potential Therapeutic Target For Human Acute T-Lymphoblastic Leukemia. Blood, 2013, 122, 1273-1273.	0.6	0